1. Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis
   Dmitry Victorovich Garbuzenko, 2015, World Journal of Gastroenterology CrossRef
2. Inhibitory effects of octreotide on the progression of hepatic fibrosis via the regulation of Bcl-2/Bax and PI3K/AKT signaling pathways
   Chong Zhang et al, 2019, International Immunopharmacology CrossRef
3. Endothelin-1 in portal hypertension: The intricate role of hepatic stellate cells
   Devaraj Ezhilarasan, 2020, Experimental Biology and Medicine CrossRef
4. Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy
   Amelia J. Hessheimer et al, 2021, Cancers CrossRef
5. Octreotide attenuates hepatic fibrosis and hepatic stellate cells proliferation and activation by inhibiting Wnt/β-catenin signaling pathway, c-Myc and cyclin D1
   Chong Zhang et al, 2018, International Immunopharmacology CrossRef
6. Aspects of pathogenetic pharmacotherapy for portal hypertension in liver cirrhosis
   D. V. Garbuzenko, 2016, Terapevticheskii arkhiv CrossRef
7. Somatostatin Therapy Improves Stellate Cell Activation and Early Fibrogenesis in a Preclinical Model of Extended Major Hepatectomy
   Amelia Hessheimer et al, SSRN Electronic Journal CrossRef
8. SP1 and UTE1 Decoy ODNs inhibit activation and proliferation of hepatic stellate cells by targeting tissue inhibitors of metalloproteinase 1
   Dong Jia et al, 2016, Cell & Bioscience CrossRef
9. Emerging therapies for portal hypertension in cirrhosis
   Harikumar Nair et al, 2016, Expert Opinion on Emerging Drugs CrossRef
10. Protective role of cortistatin in pulmonary inflammation and fibrosis
    Margarita Barriga et al, 2021, British Journal of Pharmacology CrossRef